メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

再生医療の世界市場分析と予測 (〜2022年):幹細胞・ヒト組織工学・バイオバンキング・CAR-T産業

Global Regenerative Medicine Market Analysis & Forecast to 2022; Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries

発行 Kelly Scientific Publications 商品コード 493934
出版日 ページ情報 英文 682 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.76円で換算しております。
Back to Top
再生医療の世界市場分析と予測 (〜2022年):幹細胞・ヒト組織工学・バイオバンキング・CAR-T産業 Global Regenerative Medicine Market Analysis & Forecast to 2022; Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries
出版日: 2018年06月15日 ページ情報: 英文 682 Pages
概要

世界の再生医療市場規模は、2016年の189億米ドルから2022年には660億米ドルを超える規模に拡大すると予測されています。

当レポートでは、世界の再生医療市場について分析し、アプリケーション・地域別の市場分析、主要企業の上市済み/パイプライン製品のプロファイル・財務分析・事業戦略、現在の動向、事業環境、パイプライン製品、治験、および将来の予測などについて、まとめています。

第1章 調査概要

第2章 イントロダクション

第3章 幹細胞・臨床試験

  • イントロダクション
  • 多能性幹細胞
  • 神経幹細胞
  • 内皮幹細胞または前駆細胞
  • 胎盤幹細胞
  • なぜ幹細胞の試験は失敗するのか?
  • 幹細胞治験の将来は?
  • 最先端の幹細胞治験
  • Ocata Therapeutics の現在の幹細胞治験
  • CHA Biotech の現在の幹細胞治験
  • Pfizer の現在の幹細胞治験
  • GSK の現在の幹細胞治験
  • Bayer の現在の幹細胞治験
  • Mesoblast International の現在の幹細胞治験
  • Millennium Pharmaceutical の現在の幹細胞治験
  • AstraZeneca の現在の幹細胞治験
  • Merck の現在の幹細胞治験
  • Chimerix の現在の幹細胞治験
  • エーザイの現在の幹細胞治験
  • SanBio の現在の幹細胞治験
  • Celgene の現在の幹細胞治験
  • StemCells の現在の幹細胞治験
  • Genzyme (Sanofi) の現在の幹細胞治験
  • Teva の現在の幹細胞治験
  • MedImmune の現在の幹細胞治験
  • Janssen の現在の幹細胞治験
  • Seattle Genetics の現在の幹細胞治験
  • Baxter Healthcare の現在の幹細胞治験
  • InCyte Corp の現在の幹細胞治験

第4章 幹細胞、ディスラプティブ技術、創薬および毒性試験

  • イントロダクション
  • ケーススタディ: Genentech と幹細胞技術
  • 3D培養システム
  • 幹細胞とハイスループットスクリーニング
  • 幹細胞の遺伝的不安定性
  • Comprehensive in Vitro Proarrhythmia Assay (CiPA) & 心筋細胞
  • ゲノム機能改変 (PGE) およびiPSCのカップリング
  • 幹細胞 & 毒性試験
  • 幹細胞疾患モデル
  • ヒト疾患特有の表現型の定義
  • 幹細胞由来細胞 & 薬剤スクリーニング向け組織のメリット

第5章 幹細胞バイオマーカー

  • 多能性幹細胞バイオマーカー
  • 間葉幹細胞バイオマーカー
  • 神経幹細胞バイオマーカー
  • 造血幹細胞バイオマーカー

第6章 幹細胞製品の製造

  • 幹細胞製品の製造戦略
  • 幹細胞製品のバイオプロセスエコノミクス
  • 資本投資
  • 商品原価
  • バイオプロセスエコノミクスの促進因子 & 戦略、ほか

第7章 投資 & 資金

  • 投資家は細胞 & 遺伝子療法企業から何を欲しているか?
  • 何が良い投資になるのか?
  • 投資を獲得しないのはどのタイプの企業か?
  • 世界的な資金
  • 細胞 & 遺伝子療法への投資が進む、ほか

第8章 再生医療市場の分析・予測

  • 市場概要
  • 世界の頻度分析
  • 再生医療のエコノミクス
  • 市場アプリケーション & 再生療法の機会
  • 世界の金融情勢、ほか

第9章 幹細胞市場の分析・予測

  • 自己移植 & 同種異系細胞市場の分析
  • 幹細胞市場:地域別
  • 幹細胞製品の予測:治療適応症別
  • 幹細胞試薬市場の動向

第10章 ヒト組織工学市場の分析・予測

  • 地域分析・予測
  • 地域分析:企業シェア別
  • ヒト組織工学の治験適応症分析・予測

第11章 バイオバンキング市場分析

  • 世界的な臍帯血バンク数の増加
  • 世界のバイオバンキング企業部門の分析 & 内訳
  • 同種異系 vs. 自己移植の頻度
  • バイオバンキング市場分析・予測
  • 主な世界的企業

第12章 世界の再生医療アクセス & 課題

  • 米国における再生医療市場
  • 日本における再生医療市場
  • 中国における再生医療市場
  • 韓国における再生医療市場

第13章 細胞・CAR T療法

  • 免疫療法における細胞療法およびキメラ抗原受容体発現T細胞療法 (キメラ抗原受容体発現T細胞療法) 関連の課題
  • 免疫療法に関する規制、米国におけるCAR-T および TCR免疫規制を含む
  • 日本における細胞療法 & 免疫療法の規制
  • 欧州における細胞療法 & 免疫療法の規制
  • 免疫療法の製造
  • サプライチェーン & 物流
  • 価格 & コスト分析

第14章 企業プロファイル

目次

This analysis and forecast provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global regenerative medicine market was worth $18.9 billion in 2016 and will grow to over $66 billion by 2022, with a CAGR of 23.3% between this time frame. Within this market, the stem cell industry will grow significantly at a CAGR of over x% and reach $x billion by 2022. Tissue engineering is forecast to grow at a CAGR of x% to 2022 and potentially reach $x billion. This report describes the evolution of such a huge market in 15 chapters supported by over 350 tables and figures in 680 pages.

  • An overview of regenerative medicine that includes: stem cells, allogenic and autogenic cells, umbilical cord blood banking, tissue engineering and CAR T therapies.
  • Global regenerative medicine market, global breakdown, application breakdown and leading market players
  • Detailed account of the stem cell industry market by geography, indication and company profiles
  • Profiles, marketed/pipeline products, financial analysis and business strategy of the major companies in this space
  • Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for regenerative medicine
  • Insight into the challenges faced by stakeholders, particularly about the success vs. failure ratios in developing regenerative medicine drugs and therapies.
  • Insight into the biobanking industry globally and its impact on the overall market
  • Description and data for the prevalence of disease types that are addressed by regenerative medicine, stem cells, tissue engineering and CAR-T therapies
  • Financial market forecast through 2022 with CAGR values of all market segments outlined in the objective
  • SWOT analysis of the global market
  • Geographical analysis and challenges within key topographies including the USA, Japan, South Korea, China and Europe

Key Questions Answered in this Report:

  • What is the global market for regenerative medicine from 2016 to 2022?
  • What is the global market for regenerative medicine by geography, through 2022?
  • What is the global market for regenerative medicine by indication, through 2022?
  • What is the global market for the stem cell industry from 2016 to 2022?
  • What is the global market for the stem cell industry by geography, through 2022?
  • What is the global market for the stem cell industry by indication, through 2022?
  • What disruptive technology is advancing the overall regenerative medicine market?
  • What are the major company players in the regenerative medicine, stem cells, tissue engineering and CAR-T industries?
  • What types of clinical trials are currently being performed by stakeholders and major players?
  • What are the strengths, weaknesses, opportunities and threats to the market?
  • Which geographic markets are dominating the space?
  • What are the advantages and disadvantages of the allogenic and autologous stem cell industry?
  • What are the main driving forces of this space?
  • What are the main restraints of the regenerative medicine industry as a whole?
  • What is the current environment of the global cord blood bank industry?
  • What are the global access challenges of the regenerative medicine market?
  • What is the space like in Japan, China, South Korea, USA and Europe?
  • What are the main challenges associated with CAR T therapy?
  • When will the first CAR T therapeutics be approved?
  • What are the current regulations for immunotherapies in USA, Europe & Japan?
  • What are the main manufacturing steps in CAR T therapy?
  • What challenges lie ahead for CAR T production?

Table of Contents

1.0. Report Synopsis

  • 1.1. Objectives of Report
  • 1.2. Executive Summary
  • 1.2. Key Questions Answered in this Report
  • 1.3. Data Sources and Methodology

2.0. Introduction

  • 2.1. Gurdon and Yamanaka Share the Nobel Prize
  • 2.2. Stem Cell Clinical Trials: Initiated in 2010
  • 2.3. Types of Stem Cells
  • 2.4. Adult (Tissue) Stem Cells
  • 2.5. Pluripotent Stem Cells
  • 2.6. Somatic Cell Nuclear Transfer (SCNT)
  • 2.7. Induced pluripotent Stem Cells (iPSC)
  • 2.8. Mesenchymal Cells
    • 2.8.1. MSCs in the Bone Marrow Stroma
    • 2.8.2. Isolation, Marker Specificity and Functional Properties of MSCs
    • 2.8.3. Oxygen Concentration and MSC Culture
    • 2.8.4. Assays to Define MSCs
    • 2.8.5. Differentiation Potential of MSCs
    • 2.8.6. Therapeutic Potential of MSCs
    • 2.8.7. Mesenchymal Stem Cells & Chronic Disease
    • 2.8.8. MSCs and Amylotrophic Lateral Sclerosis
    • 2.8.9. MSCs and Parkinson's Disease
    • 2.8.10. MSCs and Alzheimer Disease
    • 2.8.11. MSCs and Rheumatoid Arthritis
    • 2.8.12. MSCs and Type 1 Diabetes
    • 2.8.13. MSCs and Cardiovascular Disease
  • 2.9. Hematopoietic Stem and Progenitor Cells
    • 2.9.1. In Vivo Assays for Hematopoietic Stem Cells
    • 2.9.2. In Vitro Assays for Hematopoietic Stem and Progenitor Cells
    • 2.9.3. Isolation of Hematopoietic Stem and Progenitor Cells
    • 2.9.4. Culture of Hematopoietic Cells
    • 2.9.5. Therapeutic uses of Hematopoietic Cells
  • 2.10. Umbilical Cord Stem Cells
  • 2.11. Heart Stem Cells
    • 2.11.1. Cutting Edge Research in Heart Stem Cells
  • 2.12. Mammary Stem Cells
    • 2.12.1. Defining the Mammary Stem Cell
    • 2.12.2. Influence of Model System on Stem Cell Identification
    • 2.12.3. Breast Cancer Stem Cells
  • 2.13. Neural Stem Cells
    • 2.13.1. Identification of Neural Stem Cells
    • 2.13.2. Function of Neural Stem Cells in Vivo
    • 2.13.3. Neural Stem Cell Culture Systems
    • 2.13.4. Isolation Strategies for Neural Stem Cells
    • 2.13.5. Brain Tumour Stem Cells
    • 2.13.6. Cutting Edge Research in Neural Stem Cells
  • 2.14. Stem Cell Applications in Retinal Repair
    • 2.14.1. Embryonic Stem Cells as Retina Therapeutics
    • 2.14.2. Induced Pluripotent Stem Cells as Retina Therapeutics
    • 2.14.3. Adipose Derived Mesenchymal Stem Cells as Retina Therapeutics
  • 2.15. Liver Stem Cells
  • 2.16. Gut Stem Cells
  • 2.16. Pancreatic Stem Cells
  • 2.17. Epidermal Stem Cells

3.0. Stem Cells and Clinical Trials

  • 3.1. Introduction
  • 3.2. Pluripotent Stem Cells
  • 3.3. Limbal Stem Cells
  • 3.4. Neural Stem Cells
  • 3.5. Endothelial Stem or Progenitor Cells
  • 3.6. Placental Stem Cells
  • 3.7. Why Do Stem Cell Clinical Trials Fail?
  • 3.8. What is the Future of Stem Cell Trials?
  • 3.9. Cutting Edge Stem Cell Clinical Trials
  • 3.10. Ocata Therapeutics Current Stem Cell Trials
  • 3.11. CHA Biotech Current Stem Cell Trials
  • 3.12. Pfizer Current Stem Cell Trials
  • 3.13. GSK Current Stem Cell Trials
  • 3.14. Bayer Current Stem Cell Trials
  • 3.15. Mesoblast International Current Stem Cell Trials
  • 3.16. Millennium Pharmaceutical Current Stem Cell Trial
  • 3.17. AstraZeneca Current Stem Cell Trials
  • 3.18. Merck Current Stem Cell Trials
  • 3.19. Chimerix Current Stem Cell Trials
  • 3.20. Eisai Current Stem Cell Trials
  • 3.21. SanBio Current Stem Cell Trials
  • 3.22. Celgene Current Stem Cell Trials
  • 3.23. StemCells Current Stem Cell Trials
  • 3.24. Genzyme (Sanofi) Current Stem Cell Trials
  • 3.25. Teva Current Stem Cell Trials
  • 3.26. MedImmune Current Stem Cell Trials
  • 3.27. Janssen Current Stem Cell Trials
  • 3.28. Seattle Genetics Current Stem Cell Trials
  • 3.29. Baxter Healthcare Current Stem Cell Trials
  • 3.30. InCyte Corp Current Stem Cell Trials

4.0. Stem Cells, Disruptive Technology, Drug Discovery & Toxicity Testing

  • 4.1. Introduction
  • 4.2. Case Study: Genentech and Stem Cell Technology
  • 4.3. 3D Sphere Culture Systems
  • 4.4. Stem Cells and High Throughput Screening
    • 4.4.1. Embryonic Stem Cells
    • 4.4.2. Adult Stem Cells
    • 4.4.3. Opportunities & Challenges
  • 4.5. Genetic Instability of Stem Cells
  • 4.6. Comprehensive in Vitro Proarrhythmia Assay (CiPA) & Cardiomyocytes
  • 4.8. Coupling Precise Genome Editing (PGE) and iPSCs
  • 4.9. Stem Cells & Toxicity Testing
    • 4.9.1. Hepatotoxicity and iPSCs
    • 4.9.2. Cardiotoxicity and iPSCs
    • 4.9.3. Neurotoxicity and iPSCs
  • 4.10. Stem Cell Disease Models
  • 4.11. Defining Human Disease Specific Phenotypes
    • 4.11.1. Molecular Phenotypes for Disease Modelling
    • 4.11.2. Cellular Phenotypes for Disease Modelling
    • 4.11.3. Physiological Phenotypes for Disease Modelling
    • 4.11.4. Parkinson's Disease
    • 4.11.5. Alzheimer's Disease
    • 4.11.6. Amyotrophic Lateral Sclerosis
    • 4.11.7. Huntington's Disease
    • 4.11.8. Spinal Muscular Atrophy
    • 4.11.9. Down Syndrome
    • 4.11.10. Cystic Fibrosis
    • 4.11.11. Colorectal Cancer
  • 4.12. Advantages of Stem Cell Derived Cells & Tissues for Drug Screening

5.0. Stem Cell Biomarkers

  • 5.1. Pluripotent Stem Cell Biomarkers
  • 5.2. Mesenchymal Stem Cell Biomarkers
  • 5.3. Neural Stem Cell Biomarkers
  • 5.4. Hematopoietic Stem Cell Biomarkers

6.0. Manufacturing Stem Cell Products

  • 6.1. Manufacturing Strategies For Stem Cell Products
  • 6.2. BioProcess Economics for Stem Cell Products
  • 6.3. Capital Investment
  • 6.4. Cost of Goods
  • 6.5. Bioprocess Economic Drivers & Strategies
  • 6.6. hPSC Expansion & Differentiation using Planar Technology
  • 6.7. hPSC Expansion using 3D Culture
  • 6.8. Microcarrier Systems
  • 6.9. Aggregate Suspension
  • 6.10. Bioreactor Based Differentiation Strategy
  • 6.11. Integrated hPSC Bioprocess Strategy
  • 6.12. GMP Regulations and Stem Cell Products

7.0. Investment & Funding

  • 7.1. What do Investors Want from Cell & Gene Therapy Companies?
  • 7.2. What Makes a Good Investment?
  • 7.3. What Types of Companies do Not Get Investment?
  • 7.4. Global Funding
  • 7.5. Cell & Gene Therapy Investment Going Forward
  • 7.6. What Cell & Gene Companies are the Most Promising in 2018?
  • 7.7. Insights into Investing in Cell and Gene Therapy Companies

8.0. Regenerative Medicine Market Analysis & Forecast to 2022

  • 8.1. Market Overview
  • 8.2. Global Frequency Analysis
  • 8.3. Economics of Regenerative Medicine
  • 8.4. Market Applications & Opportunities for Regenerative Therapies
    • 8.4.1. Neurological Disease
    • 8.4.2. Autoimmune Disorders
    • 8.4.3. Cardiovascular Disease
    • 8.4.4. Diabetes
    • 8.4.5. Musculoskeletal Disorders
    • 8.4.6. Ocular Disease
    • 8.4.7. Orthopedic Disorders
    • 8.4.8. Wound Healing
  • 8.5. Global Financial Landscape
  • 8.6. Regenerative Medicine Clinical Trial Statistics
  • 8.7. Regenerative Medicine Market Forecast to 2021
  • 8.8. Regenerative Medicine Geographic Analysis and Forecast to 2021
  • 8.9. Regenerative Medicine Geographical Location of Companies
  • 8.10. Regenerative Medicine Technology Breakdown of Companies
  • 8.11. Commercially Available Regenerative Medicine Products
  • 8.12. Major Regenerative Medicine Milestones

9.0. Stem Cell Market Analysis & Forecast to 2022

  • 9.1. Autologous & Allogenic Cell Market Analysis
  • 9.2. Stem Cell Market by Geography
    • 9.2.1. North America
    • 9.2.2. Asia/Pacific
    • 9.2.3. Europe
  • 9.3. Stem Cell Market Forecast by Therapeutic Indication
    • 9.3.1. Orthopedic/Musculoskeletal Stem Cell SubMarket
    • 9.3.2. Cancer Stem Cell SubMarket
    • 9.3.3. Cardiology/Vascular Stem Cell SubMarket Analysis
    • 9.3.4. Wound Healing Stem Cell SubMarket Analysis
    • 9.3.5. Skin Stem Cell SubMarket Analysis
    • 9.3.6. Ocular Stem Cell SubMarket Forecast
  • 9.4. Stem Cell Reagent Market Trends

10.0. Tissue Engineering Tissue Engineering Market Analysis and Forecast to 2022

  • 10.1. Geographical Analysis and Forecast to 2022
    • 10.1.1. North America
    • 10.1.2. Europe
    • 10.1.3. Asia Pacific
  • 10.2. Geographical Analysis by Company Share
  • 10.3. Tissue Engineering Clinical Indication Analysis & Forecast to 2022
    • 10.3.1. Orthopedic and Musculoskeletal
    • 10.3.2. Oncology
    • 10.3.3. Cardiology and Vascular
    • 10.3.4. Dermatology
    • 10.3.5. Oral and Dental

11.0. Biobanking Market Analysis

  • 11.1. Increasing Number of Cord Blood Banks Globally
  • 11.2. Global Biobanking Company Sector Analysis & Breakdown
  • 11.3. Allogenic Versus Autologous Transplant Frequency
  • 11.4. Biobanking Market Analysis & Forecast to 2022
  • 11.5. Major Global Players

12.0. Global Access & Challenges of the Regenerative Medicine Market

  • 12.1. Regenerative Medicine Market in the USA
  • 12.2. Regenerative Medicine in Japan
    • 12.2.1. Financial Investment
    • 12.2.2. Unconventional Company Investment in Regenerative Medicine
  • 12.3. Regenerative Medicine in China
  • 12.4. Regenerative Medicine in South Korea

13.0. Cell and CAR T Therapy

  • 13.1. Challenges Relating to Cell therapy and Chimeric Antigen Receptor T Cells in Immunotherapy
    • 13.1.1. Clinical Status of CD19 CAR-T Cells To Date
    • 13.1.2. Clinical and Regulatory Challenges for Development of CAR T Cells
    • 13.1.3. Key Regulatory Challenges Associated with CAR-T Development
    • 13.1.4. Summary of Select CAR-T Products by Juno, Novartis and Kite
    • 13.1.5. Clinical Benefit Versus Toxicity in CD19-Directed ALL Clinical Trials
    • 13.1.6. How to Manage Toxicity of CAR-T Therapy
  • 13.2. Regulations Pertaining to Immunotherapy, including Adoptive Cell Therapy (CAR-T and TCR) Immunotherapy Regulation in the USA
    • 13.2.1. Center for Biologics Evaluation and Research (CBER)
    • 13.2.2. Compliance and Surveillance
    • 13.2.3. Extra Resources on Immunotherapeutics from the FDA
    • 13.2.4. Cellular, Tissue and Gene Therapies Advisory Committee
    • 13.2.5. Consumer Affairs Branch (CBER) Contact in FDA
    • 13.2.6. FDA Regulations Pertaining to Immunotherapies
    • 13.2.7. Case Study Ovarian Cancer Immunotherapy Regulations
      • 13.2.7.1. Efficacy
      • 13.2.7.2. Adverse Effects
    • 13.2.8. Trial Design Considerations for Immunotherapy
    • 13.2.9. Development of Immune-Related Response Criteria (irRC) & Clinical Endpoints Specific to Immunotherapies
  • 13.3. Regulations for Cell Therapy & Immunotherapy in Japan
    • 13.3.1. PMDA and Cell Therapy & Immunotherapy
    • 13.3.2. Increasing the Efficiency in Cell Therapy & Immunotherapy Regulatory Review
    • 13.3.3. Forerunner Review Assignment System
    • 13.3.4. Revised Guidelines for Clinical Evaluation of Anti-Malignant Tumor Agents
    • 13.3.5. Key Contacts Within the PMDA for Cell Therapy & Immunotherapeutics
  • 13.4. European Regulation and Cell Therapy & Immunotherapeutics
    • 13.4.1. Introduction
    • 13.4.2. Challenges for Cell Therapy & Immunotherapy in EMEA
    • 13.4.3. EMA Status on Potency Testing
      • 13.4.3.1. In Vivo Potency Testing
      • 13.4.3.2. In Vitro Potency Testing
      • 13.4.3.3. Viable Cell Count
      • 13.4.3.4. Autologous Cell Based Products
      • 13.4.3.5. Reference Preparation
      • 13.4.3.6. Adjuvant Containing Immunotherapy Products
    • 13.4.4. EMA Status on Identifying hyper, Hypo or non-Responders
    • 13.4.5. Challenges Relating to Biomarkers in Immunotherapy
    • 13.4.6. Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy
    • 13.4.7. Estimating Optimal Cut-Off Parameters
    • 13.4.8. EU-Approved Immunotherapies in Melanoma
    • 13.4.9. Key Contacts Within EMA for Cell Therapy & Immunotherapeutics
  • 13.5. Manufacturing of Immunotherapies
    • 13.5.1. Introduction
    • 13.5.2. Generation of CAR-Modified T Cells
    • 13.5.3. What Co-Stimulation and Activity Domain is Optimal to Use?
    • 13.5.4. Optimizing Cell Culture Media
    • 13.5.5. Manufacturing Lentiviral Vectors
    • 13.5.6. Detection of Integrated CAR-Expressing Vectors
    • 13.5.7. Donor Lymphocyte Infusion Procedure
    • 13.5.8. Ex Vivo Costimulation & Expansion of Donor T Cells
    • 13.5.9. Infusion to the Patient
    • 13.5.10Manufacturing Devices and Instruments Required for Immunotherapy Production
      • 13.5.10.1. Leukapheresis
      • 13.5.10.2. Cell Counters and Analyzer
      • 13.5.10.3. Cell Seeding, Growth and Propagation
    • 13.5.11Good Manufacturing Procedure (GMP) for Immunotherapy
    • 13.5.12Case Study Production of Lentivirus Induced Dendritic Cells under GMP Conditions
    • 13.5.13Quality Control
    • 13.5.14Regulatory Affairs
    • 13.5.15Key Challenges in Manufacturing
      • 13.5.15.1. Electroporation of T-cells
      • 13.5.15.2. Allogenic CAR T cells
      • 13.5.15.3. Relapse Rates are Critical
      • 13.5.15.4. Antigen Negative Relapse
      • 13.5.15.5. Incorporating Suicide Genes
    • 13.5.16Automation in Cell Therapy Manufacturing
    • 13.5.17Autologous Cell Therapy Manufacture Scale Up
  • 13.6. Supply Chain & Logistics
    • 13.6.1. Introduction
    • 13.6.2. Case Study: Juno Therapeutics
  • 13.7. Pricing & Cost Analysis
    • 13.7.1. Introduction
    • 13.7.2. CAR T Therapy Market Evaluation
    • 13.7.3. Current Deals Within the CAR T Market

14.0. Company Profiles

  • 14.1. Astellas Institute for Regenerative Medicine (Ocata Therapeutics)
    • 14.1.1. Company Background
    • 14.1.2. Products
    • 14.1.3. Financials
    • 14.1.4. Company Strategy
  • 14.2. Athersys
    • 14.2.1. Company Background
    • 14.2.2. Products
    • 14.2.3. Financial Analysis
    • 14.2.4. Company Strategy
  • 14.3. Baxter International (Baxalta, Shire)
    • 14.3.1. Company Background
    • 14.3.2. Financial Analysis
    • 14.3.3. Company Strategy
  • 14.4. Caladrius Biosciences (NeoStem)
    • 14.4.1. Company Details
    • 14.4.2. Products
      • 14.4.2.1. CLBS20
      • 14.4.2.2. CLBS03 Treg Cellular Therapy
      • 14.4.2.3. CLBS12 CD34 Cell Therapy
    • 14.4.3. Financial Analysis
    • 14.4.4. Company Strategy
  • 14.5. Cynata Therapeutics
    • 14.5.1. Company Background
    • 14.5.2. Product Details
    • 14.5.3. Financial Data
    • 14.5.4. Company Strategy
  • 14.6. Cytori Therapeutics
    • 14.6.1. Company Products
    • 14.6.2. Financial Analysis
    • 14.6.3. Company Strategy
  • 14.7. MEDIPOST
    • 14.7.1. Company Details
    • 14.7.2. Company Products
      • 14.7.2.1. CellTree Umbilical Cord Blood Bank
      • 14.7.2.2. CARTISTEM®
      • 14.7.2.3. NEUROSTEM®
      • 14.7.2.4. PNEUMOSTEM ®
    • 14.7.3. Financial Analysis
  • 14.8. Mesoblast
    • 14.8.1. Company Details
      • 14.8.1.1. Unique Features of Mesoblast and its Disruptive Technology
      • 14.8.1.2. Allogeneic Mesenchymal Lineage Adult Stem Cells (MLCs)
      • 14.8.1.3. Mechanism of Action of MLC Products
      • 14.8.1.4. Manufacturing of Mesoblast MLC-Based Products
      • 14.8.1.5. Mesoblast Patent Portfolio
    • 14.8.2. Mesoblast Product Portfolio
      • 14.8.2.1. MSC-100-IV/TEMCELL® for Acute Graft Versus Host Disease (aGVHD)
      • 14.8.2.2. MPC-150-IM - Chronic Heart Failure (CHF)
      • 14.8.2.3. MPC-25-IC for Acute Myocardial Infarction
      • 14.8.2.4. MPC-06-ID - Chronic Low Back Pain (CLBP) due to Degenerative Disc Disease (DDD)
      • 14.8.2.5. MPC-300-IV for Biologic-Refractory Rheumatoid Arthritis
      • 14.8.2.6. MPC-300-IV for Diabetic Nephropathy
      • 14.8.2.7. MPC-100-IV for Crohn's Disease
      • 14.8.2.8. MPC-25-Osteo for Spinal Fusion
    • 14.8.3. Mesoblast International Strategic Business Collaborations
    • 14.8.4. Mesoblast Financial Analysis
  • 14.9. NuVasive
    • 14.9.1. Company Details
    • 14.9.2. Biologic Products for the Spinal Surgery Market
      • 14.9.2.1. Formagraft
      • 14.9.2.2. AttraX
      • 14.9.2.3. Propel DBM
      • 14.9.2.4. Osteocel Plus and Pro
    • 14.9.3. Financial Analysis
    • 14.9.4. Company Business Strategy
  • 14.10. Osiris Therapeutics
    • 14.10.1. Company Profile
      • 14.10.1.1. BioSmart Cryopreservation Technology
      • 14.10.1.2. MSC Primer Technology
    • 14.10.2. Products
      • 14.10.2.1. Grafix
      • 14.10.2.2. BIO 4
      • 14.10.2.3. Cartiform
      • 14.10.2.4. Stravix
    • 14.10.3. Company Financial Analysis
    • 14.10.4. Company Strategy
  • 14.11. Plasticell
    • 14.11.1Company Profile
  • 14.12. Pluristem Therapeutics
    • 14.12.1. Company Profile
    • 14.12.2. Products
      • 14.12.2.1. PLacental eXpanded (PLX) Cells
      • 14.12.2.2. PLX-PAD
      • 14.12.2.3. PLX-R18
    • 14.12.3. Financial Analysis
    • 14.12.4. Business Strategy
  • 14.13. Pfizer
    • 14.13.1. Company Profile
  • 14.14. StemCells Inc
    • 14.14.1. Company Profile
    • 14.14.2. HuCNS-SC Platform Technology
    • 14.14.3. Clinical Trial Analysis
    • 14.14.4. Financial Analysis
  • 14.15. STEMCELL Technologies
    • 14.15.1. Company Details
    • 14.15.2. Product Details
  • 14.16. Takara Bio
    • 14.16.1. Company Details
    • 14.16.2. Product Portfolio
      • 14.16.2.1. HF10 Anti-Cancer Therapy
      • 14.16.2.2. TCR Gene Therapy
      • 14.16.2.3. MazF Gene Therapy
    • 14.16.3. Centre for Cell and Gene Processing
    • 14.16.4. Company Financials
    • 14.16.5. Company Strategy
  • 14.17. Tigenix
    • 14.17.1. Company Background
    • 14.17.2. Products
    • 14.17.3. Financial Data
    • 14.17.4. Company Strategy

15.0. SWOT Industry Analysis

  • 15.1. What has Strengthened the Industry Thus Far?
  • 15.2. Allogenic and Autologous Stem Cell Industry SWOT Analysis
  • 15.3. What are the Main Driving Forces of this Space?
  • 15.4. Restraints of the Regenerative Medicine Industry as a Whole
  • 15.5. Industry Opportunities Within this Sector
  • 15.6. USA SWOT Analysis
    • 15.6.1. Growth Opportunities
    • 15.6.2. Drivers
    • 15.6.3. Market Challenges
  • 15.7. UK SWOT Analysis
    • 15.7.1. Growth Opportunities
    • 15.7.2. Drivers
    • 15.7.3. Market Challenges
  • 15.8. South Korea SWOT Analysis
    • 15.8.1. Growth Opportunities
    • 15.8.2. Drivers
    • 15.8.3. Market Challenges
  • 15.9. China SWOT Analysis
    • 15.9.1. Growth Opportunities
    • 15.9.2. Drivers
    • 15.9.3. Challenges
  • 15.10. Japan SWOT Analysis
    • 15.10.1. Opportunities
    • 15.10.2. Market Drivers
    • 15.10.3. Challenges
  • 15.11. Singapore SWOT Analysis
    • 15.11.1. Opportunities
    • 15.11.2. Market Drivers
    • 15.11.3. Challenges

List of Exhibits

  • Exhibit 2.1: Stem Cell Discovery and Development Timeline
  • Exhibit 2.2: Potential Therapeutic Uses of Stem Cells
  • Exhibit 2.3: Embryonic Stem Cell Differentiation
  • Exhibit 2.4: Pluripotent Stem Cells
  • Exhibit 2.5: Clinical Uses of Stem Cells
  • Exhibit 2.6: Illustration of Inner Cell Mass Generation for Stem Cell Culture
  • Exhibit 2.7: Drug Development Strategies for Patient Derived iPSCs
  • Exhibit 2.8: Mesenchymal Stem Cell Lineage Progression & Differentiation
  • Exhibit 2.9: Mesenchymal Stem Cell Differentiation
  • Exhibit 2.10: Potential Therapeutic Effects of MSCs
  • Exhibit 2.11: Hematopoietic Stem Cells & the Formation of Mature Blood Cells
  • Exhibit 2.12: Donor Types for HSC transplantation
  • Exhibit 2.13: Total Number of Stem Cell Donors 1989-Present
  • Exhibit 2.14: Cross Section of Umbilical Cord Sample for Stem Cell Extraction
  • Exhibit 2.15: Umbilical Cord Blood and Wharton's Jelly; Sources of HSCs and MSCs
  • Exhibit 2.16: Comprehensive List of Conditions Treated by Cord Blood Transplants
  • Exhibit 2.17: Cardiac Progenator Cell Populations
  • Exhibit 2.18: Transplanted Cardiac Progenitor Cells: Potential Mechanism of Action in the Myocardium
  • Exhibit 2.19: Mammary Stem Cells in the Presence and Absence of Hormones
  • Exhibit 2.20: Mammary Stem Cell Tree Following Transplantation
  • Exhibit 2.21: Production of Neurons, Astrocytes and Oligodendrocytes from Neural Stem Cells
  • Exhibit 2.22: Physiology of the Eye
  • Exhibit 2.23: Physiological Functions of Each Eye Component
  • Exhibit 2.24: Healthy & Degenerated Retinal Pigment Epithelium
  • Exhibit 2.25: Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium
  • Exhibit 2.26: Using Stem Cells to Replace Dysfunctional Retinal Pigment Epithelial Cells
  • Exhibit 2.27: Using Stem Cells to Replace Retinal Nerve Cells
  • Exhibit 2.28: Stem Cells Located Around the Central Vein in the Liver
  • Exhibit 2.29: Gut Stem Cells are Located in the Crypts of Lieberhahn
  • Exhibit 2.30: Localization of Epidermal & Dermal Stem Cells
  • Exhibit 3.1: Current Therapeutic Areas and Disease States with Number of Stem Cell Clinical Trials, Globally
  • Exhibit 3.2: Current Geographical Location and Number of Stem Cell Clinical Trials, Globally
  • Exhibit 3.3: Current Geographical Location and Number of Stem Cell Clinical Trials, USA
  • Exhibit 3.4: Current Geographical Location and Number of Stem Cell Clinical Trials, Europe
  • Exhibit 3.5: Current Geographical Location and Number of Stem Cell Clinical Trials, East Asia
  • Exhibit 3.6: Select hESC and iPSC-Based Products in Clinical Trials by Disease, Stage and Trial Status
  • Exhibit 3.7: Selected Studies and Key Findings of PSC-Based Therapies in Development for AMD, Diabetes, Liver Disease, Parkinson's and Thalassemia
  • Exhibit 3.8: Ocata Therapeutics Current Stem Cell Trials, Globally
  • Exhibit 3.9: CHA Biotech Current Stem Cell Trials, Globally
  • Exhibit 3.10: Pfizer Current Stem Cell Trials, Globally
  • Exhibit 3.11: GSK Current Stem Cell Trials, Globally
  • Exhibit 3.12: Bayer Current Stem Cell Trials, Globally
  • Exhibit 3.13: Mesoblast International Current Stem Cell Trials, Globally
  • Exhibit 3.14: Millennium Pharmaceutical Current Stem Cell Trials, Globally
  • Exhibit 3.15: AstraZeneca Current Stem Cell Trials, Globally
  • Exhibit 3.16: Merck Current Stem Cell Trials, Globally
  • Exhibit 3.17: Chimerix Current Stem Cell Trials, Globally
  • Exhibit 3.18: Eisai Current Stem Cell Trials, Globally
  • Exhibit 3.19: SanBio Current Stem Cell Trials, Globally
  • Exhibit 3.20: Celgene Current Stem Cell Trials, Globally
  • Exhibit 3.21: StemCells Current Stem Cell Trials, Globally
  • Exhibit 3.22: Genzyme (Sanofi) Current Stem Cell Trials, Globally
  • Exhibit 3.23: Teva Current Stem Cell Trials, Globally
  • Exhibit 3.24: MedImmune Current Stem Cell Trials, Globally
  • Exhibit 3.25: Janssen Current Stem Cell Trials, Globally
  • Exhibit 3.26: Seattle Genetics Current Stem Cell Trials, Globally
  • Exhibit 3.27: Baxter Healthcare Current Stem Cell Trials, Globally
  • Exhibit 3.28: InCyte Corp Current Stem Cell Trials, Globally
  • Exhibit 4.1: Disease Models Generated from iSPC using Genome Editing
  • Exhibit 4.2: Stem Cells Used for Drug Screening
  • Exhibit 4.3: Sucessful Human iPSC Mediate Therapy Cases
  • Exhibit 4.4: Number of US Patients That Could Benefit From Stem Cell Therapeutics
  • Exhibit 4.5: Genentechs Stem Cell Platform for Drug & Toxicity Screening
  • Exhibit 4.6: Key Challenges in Assessing Genetic Instability of Stem Cells
  • Exhibit 4.7: Comprehensive In Vitro Proarrhythmia Assay (CiPA) Components
  • Exhibit 4.8: Ex Vivo Gene Therapy and Stem Cell Technology
  • Exhibit 4.9: Genome Editing and iPSCs
  • Exhibit 4.10: Gene Edited iPSC/hES-Mediated Novel Therapy Development
  • Exhibit 4.11: Comparison of 3D and 2D Cultures of iPSC-Derived Hepatocytes Following Treatment with Toxins, Anti-Proliferative Agents and Other Drugs
  • Exhibit 4.12: Potential Applications of Human iPSCs for Liver Diseases
  • Exhibit 4.13: Myocardial Tissue: Cardiomyocytes, Endothelial Cells and Fibroblasts
  • Exhibit 4.14: Cardiovascular Disease-Specific Human Pluripotent Stem Cell Lines by Genetic Cause and Drug Testing
  • Exhibit 4.15: Culture of Human iPSC-Derived Dopaminergic Neurons over 14 Days
  • Exhibit 4.16: Strategies for Generating Disease Models Using Human Pluripotent Stem Cells (PSCs)
  • Exhibit 4.17: Criteria for Disease Modelling Using Pluripotent Stem Cells
  • Exhibit 4.18: Models of Monogenic Dominant Diseases
  • Exhibit 4.19: Models of Monogenic Recessive Diseases
  • Exhibit 4.20: Models of Monogenic X-linked Recessive Diseases
  • Exhibit 4.21: iPSCs in Neurological Disease Modeling, Drug Screening & Cell Therapy
  • Exhibit 4.22: Advantages and Uses of Intestinal Organoids
  • Exhibit 5.1: Main Biomarkers Associated with Pluripotent Stem Cells
  • Exhibit 5.2: Pluripotent Stem Cell Biomarkers
  • Exhibit 5.3: Main Biomarkers Associated with Mesenchymal Stem Cells
  • Exhibit 5.4: Mesenchymal Stem Cell Biomarkers
  • Exhibit 5.5: Main Biomarkers Associated with Neural Stem Cells
  • Exhibit 5.6: Neural Stem Cell Biomarkers
  • Exhibit 5.7: Main Biomarkers Associated with Hematopoietic Stem Cells
  • Exhibit 5.8: Hematopoietic Stem Cell Biomarkers
  • Exhibit 6.1: Bioprocess Development Considerations for hPSC-Derived Products
  • Exhibit 6.2: Technologies Used for Expansion & Differentiation of hPSC-Derived Cell Products
  • Exhibit 6.3: Comparison of Key Performance Characteristics of Cardiomyocytes, Hepatocytes, Neurons, Neural Progenitor Cells, Endoderm Progenitors and Hepatocytes in Planar & Bioreactor Based Differentiation Protocols
  • Exhibit 6.4: Integrated Expansion & Differentiation of hPSCs Studies by Cell, Process, Cell Density, Process Time and Target Cells Produced
  • Exhibit 6.5: hPSC Bioprocess Strategies, Planar, Segregated 3D & Integrated: Advantages & Disadvantages
  • Exhibit 6.6: Main Objectives of GMP Manufacturing
  • Exhibit 6.7: GMP Facilities Required for Stem Cell Product Manufacuring
  • Exhibit 6.8: Manufacturing Overview of hIPSCs under GMP Regulation
  • Exhibit 6.9: Key Steps in Manufacturing GMP Regulated iPSCs
  • Exhibit 6.10: Characterization and Release Assays for Human iPSCs Manufactured under GMP Conditions
  • Exhibit 6.11: MCB Viral Assays for use on Human iPSCs Bank
  • Exhibit 6.12: Differences Between Autologous & Allogeneic Cell Therapy Models
  • Exhibit 7.1: Selected Venrock Biotech and Healthcare Exits
  • Exhibit 7.2: Stem Cell Funding Bodies, Globally
  • Exhibit 7.3: Stem Cell Societies and Consortiums by Geography
  • Exhibit 7.4: Total Stem Cell NIH Funding 2014-2017
  • Exhibit 7.5: NIH Funded Stem Cell Related Projects 2014-2017
  • Exhibit 7.6: Tabular Data NIH Funded Stem Cell Related Projects 2014-2017
  • Exhibit 7.7: CIRM Investment Funding by Stem Cell Type
  • Exhibit 7.8: CIRM Stem Cell Project Investment Funding by Therapeutic Area
  • Exhibit 7.9: Promising Cell & Gene Companies
  • Exhibit 8.1: Global Frequency Indicator Trend of Terms Regenerative Medicine, Cell Therapy and Tissue Engineering, 2007-2017
  • Exhibit 8.2: GeoMap Frequency Indicator Trend of Terms Regenerative Medicine, Cell Therapy and Tissue Engineering, 2007-2017
  • Exhibit 8.3: Increased Proportion of People Over 65 Through 2050
  • Exhibit 8.4: Percentage of Global Population Aged 65 Plus 2015-2050
  • Exhibit 8.5: Global Alzheimer's Disease Market Forecast 2016-2020
  • Exhibit 8.6: Global Cardiovascular Market Forecast 2016-2020
  • Exhibit 8.7: Global Diabetes Therapy and Device Market Forecast 2016-2020
  • Exhibit 8.8: Bone Graft Global Market Forecast 2016-2020
  • Exhibit 8.9: Bone Graft Global Market Forecast to 2020 by Geography
  • Exhibit 8.10: Total Global Financings of the Regenerative Medicine, Cell and Gene Therapy and Tissue Engineering Sector
  • Exhibit 8.11: Total Global Financing of Regenerative Medicine & Cellular/Gene Therapy by Type
  • Exhibit 8.12: Number of Global Clinical Trials by Phase of Regenerative Medicine, Cell and Gene Therapy Studies, 2015
  • Exhibit 8.13: Number of Global Clinical Trials by Indication of Regenerative Medicine, Cellular & Gene Therapeutics, 2015
  • Exhibit 8.14: Major Clinical Trial Events in Regenerative Medicine 2016
  • Exhibit 8.15: Global Regenerative Medicine Market Value Tabular Forecast 2016-2022
  • Exhibit 8.16: Global Regenerative Medicine Market Value Forecast 2016-2022
  • Exhibit 8.17: Regenerative Medicine Geographic Analysis and Forecast to 2022
  • Exhibit 8.18: Regenerative Medicine Geographic Forecast Table to 2022
  • Exhibit 8.19: Regenerative Medicine Market Share by Geography 2016
  • Exhibit 8.20: Regenerative Medicine Market Share Forecast by Geography 2022
  • Exhibit 8.21: North America Regenerative Medicine Forecast to 2022
  • Exhibit 8.22: European Regenerative Medicine Forecast to 2022
  • Exhibit 8.23: Asia Pacific Regenerative Medicine Forecast to 2022
  • Exhibit 8.24: RoW Regenerative Medicine Forecast to 2022
  • Exhibit 8.25: Geographical Location of Regenerative Medicine Companies
  • Exhibit 8.26: Regenerative Medicine Technology Breakdown of Companies
  • Exhibit 8.27: Number and Geographical Location of Regenerative Medicine, Cellular Therapy & Gene Therapy Companies, Globally
  • Exhibit 8.28: Select FDA-Approved Regenerative Medicine Products by Biologics. Cell Based and Biopharmaceuticals
  • Exhibit 8.29: Regulatory Approved & Commercialized Regenerative Medicine Products Currently on the Market
  • Exhibit 8.30: Major Regenerative Medicine Milestones in 2016
  • Exhibit 9.1: Global Stem Cell Therapy Market Forecast Table 2016-2022
  • Exhibit 9.2: Global Stem Cell Therapy Market Forecast 2016-2022
  • Exhibit 9.3: Stem Cell Market Share by Adult and Embryonic Stem Cells and Stem Cell Banking
  • Exhibit 9.4: Major Clinical Trial Events in Stem Cell Medicine 2016
  • Exhibit 9.5: Stem Cell Geographic Market Share Forecast 2016-2022
  • Exhibit 9.6: Global Stem Cell Market Share by Geographic Region 2016
  • Exhibit 9.7: Global Stem Cell Market Share by Geographic Region 2022
  • Exhibit 9.8: North American Stem Cell Market Forecast 2016-2022
  • Exhibit 9.9: Asia Pacific Stem Cell Market Forecast 2016-2022
  • Exhibit 9.10: European Stem Cell Market Forecast 2016-2022
  • Exhibit 9.11: Rest of the World Stem Cell Market Forecast 2016-2022
  • Exhibit 9.12: Market Share of Top Therapeutic Indications in Stem Cell Space, 2016
  • Exhibit 9.13: Market Share of Top Therapeutic Indications in Stem Cell Space, 2022 Forecast
  • Exhibit 9.14: Stem Cell Market Forecast by Therapeutic Indications 2016-2022
  • Exhibit 9.15: Orthopedic/Musculoskeletal Stem Cell SubMarket Forecast 2016-2022
  • Exhibit 9.16: Cancer Stem Cell SubMarket Forecast 2016-2022
  • Exhibit 9.17: Cardiology/Vascular Stem Cell SubMarket Forecast 2016-2022
  • Exhibit 9.18: Wound Healing Stem Cell SubMarket Forecast 2016-2022
  • Exhibit 9.19: Skin Stem Cell Products and Sources
  • Exhibit 9.20: Skin Stem Cell SubMarket Forecast 2016-2022
  • Exhibit 9.21: Ocular Stem Cell SubMarket Forecast 2016-2022
  • Exhibit 9.22: Current Top Brands Being Used for Stem Cell R&D
  • Exhibit 9.23: Most Frequent Method of Obtaining Stem Cell Lines in R&D
  • Exhibit 9.24: Percentage of Stem Cell Characterization Analysis Kits Used in R&D
  • Exhibit 9.25: Percentage of Stem Cell Differentiation Kits Used in R&D
  • Exhibit 9.26: Most Common Types of Stem Cells Used in R&D by Mouse, Human & Rat Origin
  • Exhibit 10.1: Global Tissue Engineering Market Tabular Forecast to 2021
  • Exhibit 10.2: Global Tissue Engineering Market Forecast to 2021
  • Exhibit 10.3: Global Tissue Engineering Market Forecast by Geographic Region 2016-2022
  • Exhibit 10.4: North America Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.5: Europe Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.6: Asia Pacific Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.7: Geographical Breakdown of Tissue Engineering Companies Globally
  • Exhibit 10.8: Public and Privately Held Tissue Engineering Company Distribution, Globally
  • Exhibit 10.9: Main Players in the Tissue Engineering Market
  • Exhibit 10.10: Main Players in the CAR-T Market
  • Exhibit 10.11: Main Players in the TCR Market
  • Exhibit 10.12: Main Players in the NK Cell Market
  • Exhibit 10.13: Main Players in the TILs Market
  • Exhibit 10.14: Global Tissue Engineering Submarket Breakdown by Market Share 2016
  • Exhibit 10.15: Global Tissue Engineering Submarket Breakdown by Market Share Forecast 2022
  • Exhibit 10.16: Tissue Engineering Submarket Breakdown Forecast Table 2016-2022
  • Exhibit 10.17: Tissue Engineering Submarket Breakdown Forecast 2016-2022
  • Exhibit 10.18: Orthopedics/Musculoskeletal Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.19: Oncology Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.20: Cardiology and Vascular Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.21: Dermatology Tissue Engineering Market Forecast 2016-2022
  • Exhibit 10.22: Oral and Dental Tissue Engineering Market Forecast 2016-2022
  • Exhibit 11.1: Number of Stem Cell Donors by Geographical Location
  • Exhibit 11.2: Number and Geographical Location of Global Unrelated Cord Blood Units
  • Exhibit 11.3: Market Share of Companies in the BioBanking Industry
  • Exhibit 11.4: Market Share within Therapeutic Companies in the BioBanking Industry
  • Exhibit 11.5: Market Share within Cell & Tissue Banks in the BioBanking Industry
  • Exhibit 11.6: Percentage of Allogenic & Autologous Transplantations
  • Exhibit 11.7: Percentage Breakdown of Indications using Autologous Umbilical Cord Blood Transplants
  • Exhibit 11.8: Percentage Breakdown of Indications using Allogenic Umbilical Cord Blood Transplants
  • Exhibit 11.9: Global Cord Blood Banking Market Forecast 2016-2022
  • Exhibit 11.10: Stem Cell Biobanking Market Segments
  • Exhibit 11.11: Top Global Cord Blood and Tissue Companies
  • Exhibit 11.12: Important Players in the International Private Cord Bank Market
  • Exhibit 12.1: Key Challenges to the Regenerative Medicine & Cellular/Gene Therapy Market
  • Exhibit 12.2: Company and Indication that will Benefit from New 21st Century Cures Act, USA
  • Exhibit 12.3: Cell and Gene Based Therapy in Japan as Defined by the PMDA
  • Exhibit 12.4: Regulatory System in Japan for Regenerative Medicine and Cell and Gene Therapy Products
  • Exhibit 12.5: Main Stem Cell Research Institutes in China
  • Exhibit 13.1: Selected CD19-directed Product Candidates in Clinical Trials by Costimulatory & Binding Domains, Starting Cell Population, Vector and Ablation Technology
  • Exhibit 13.2: Select CD19-Directed ALL Clinical Trials
  • Exhibit 13.3: Select Anti-CD22 CAR-T Clinical Projects
  • Exhibit 13.4: CBER Compliance and Surveillance Activities
  • Exhibit 13.5: Contacts for the Cellular, Tissue and Gene Therapies Advisory Committee, FDA
  • Exhibit 13.6: Clinical Regulatory Pathway - Conventional Route
  • Exhibit 13.7: Clinical Regulatory Pathway - Option for Rapid Translation
  • Exhibit 13.8: PMDA Total Review Period of Standard Drugs
  • Exhibit 13.9: PMDA Total Review Period of Priority Drugs
  • Exhibit 13.10: Number of Approved Recombinant Protein Products by PMDA 1985-2013
  • Exhibit 13.11: Forerunner Review Assignment System Timeframe
  • Exhibit 13.12: Adaptive Licensing and Accelerated Approval in Japan-US-EU
  • Exhibit 13.13: Key Contacts Within PMDA, Japan
  • Exhibit 13.14: CheckMate 066 Clinical Trial
  • Exhibit 13.15: CheckMate 037 Clinical Trial
  • Exhibit 13.16: Contact Details for EMA Cell Therapy & Immunotherapy Experts
  • Exhibit 13.17: Method of Generating CAR-Modified T Cells
  • Exhibit 13.18: Clinical Activity, Cost Structure and Patient Convenience Flow Chart of CAR-T Therapy
  • Exhibit 13.19: General Technical and Personnel Requirements of a GMP, QC, QA, FDA Regulated Cell Therapy Manufacturing Facility
  • Exhibit 13.20: Technician/Scientific Requirements for CAR T Manufacturing
  • Exhibit 13.21: Selection of Apheresis Instruments Currently on the Market
  • Exhibit 13.22: Selection of Cell Counters and Analyzer Instruments Currently on the Market
  • Exhibit 13.23: Main Objectives of GMP Manufacturing Immunotherapeutics
  • Exhibit 13.24: Main Objectives of Quality Control While Manufacturing Immunotherapeutics
  • Exhibit 13.25: Main Objectives of Regulatory Affairs During Manufacturing Immunotherapeutics
  • Exhibit 13.26: CAR-T Studies Using mRNA Transfection Electroporation
  • Exhibit 13.27: Allogenic Versus Autologous Cell Manufacturing
  • Exhibit 13.28: Challenges for Autologous Cell Therapy Manufacture
  • Exhibit 13.29: Current Company/Institutions with Suicide Gene CAR T Projects
  • Exhibit 13.30: Advantages of Using Automated Cell Therapy Manufacturing
  • Exhibit 13.31: Main Drivers to Implement Automated Cell Therapy Manufacturing
  • Exhibit 13.32: Main Benefits of Automated Cell Therapy Manufacturing
  • Exhibit 13.33: Advantages & Disadvantages of Autologous Cell Therapy Manufacture Scale Up
  • Exhibit 13.34: Streptamer® -Based Magnetic Bead Cell Isolation Exhibit 13.35 Juno Therapeutics Manufacturing Facility Objectives
  • Exhibit 13.36: Annual Cost of Patented Cancer Therapeutics from 2000 to Today
  • Exhibit 13.37: Cost of Nivolumab, Pembrolizumab & Ipilimumab per mg
  • Exhibit 13.38: Current Juno Therapeutics Trials and CAR T Products
  • Exhibit 13.39: Current CAR T Business Deals
  • Exhibit 14.1: MultiStem Platform in Action
  • Exhibit 14.2: Key Advantages of MultiStem
  • Exhibit 14.3: Athersys Product and Clinical Pipeline
  • Exhibit 14.4: Athersys Key Business Strategies
  • Exhibit 14.5: Baxter International Product Revenue by Class
  • Exhibit 14.6: Baxter International Product Revenue by Geography
  • Exhibit 14.7: Baxter International Breakdown of Product Revenue
  • Exhibit 14.8: Caladrius Expertise in Cell Type and Therapeutic Application Portfolio
  • Exhibit 14.9: PCT Caladrius CLBS03 Treg Cellular Therapy Manufacturing Process
  • Exhibit 14.10: Caladrius Revenue 2014-2016
  • Exhibit 14.11: Caladrius Clinical Manufacturing Revenue 2014-2016
  • Exhibit 14.12: Caladrius Process Development Revenue 2014-2016
  • Exhibit 14.13: Cytori Cell Therapy Mechanism of Action in Angiogenesis, Inflammation and Wound Remodeling
  • Exhibit 14.14: Cytori Therapeutics Cell Therapy Clinical Pipeline
  • Exhibit 14.15: MediPost Product Pipeline by Indication and Clinical Study Phase
  • Exhibit 14.16: Medipost Sales Figures 2013-2016
  • Exhibit 14.17: CellTree Umbilical Cord Blood Bank Program Details and Pricing
  • Exhibit 14.18: Medipost Revenue Share by Product Category 2016
  • Exhibit 14.19: Medipost Sales Revenue by Product Category 2012-2016
  • Exhibit 14.20: Medipost Umbilical Cord Blood Bank Revenue 2012-2016
  • Exhibit 14.21: Medipost Stem Cell Drug Sales Revenue 2012-2016
  • Exhibit 14.22: Medipost R&D Investment 2012-2016
  • Exhibit 14.23: Mesenchymal Lineage Adult Stem Cells (MLCs) Secrete a Variety of Immunomodulatory Molecules
  • Exhibit 14.24: Mesoblast Mesenchymal Lineage Adult Stem Cell (MLC) Functional Properties
  • Exhibit 14.25: Mesoblast Expanion and Immune Privilege of MLC Technology
  • Exhibit 14.26: Mesoblast Complementary Technology Platforms
  • Exhibit 14.27: Mechanism of Action of MPC-150-IM, MPC-06-ID, MPC-300-IV, TEMCELL(R)HS. Inj. and MSC-100-IV and MPC-25-OSTEO
  • Exhibit 14.28: Mesoblast MLC-Based Product Manufacturing and Distribution Process
  • Exhibit 14.29: Mesoblast Patent Portfolio with Expiration and Validity through 2035
  • Exhibit 14.30: Mesoblast Tier 1 and Tier 2 Product Candidates by Program and Clinical Stage
  • Exhibit 14.31: Mesoblast Lead Product MSC-100-IV/TEMCELL HS Inj
  • Exhibit 14.32: MSC-100-IV Treatment in Children with SR-aGVHD who Failed Other Modalities
  • Exhibit 14.33: MPC-300-IV for Treatment of Chronic Inflammatory Diseases
  • Exhibit 14.34: Mesoblast International Strategic Business Collaborations
  • Exhibit 14.35: Mesoblast FY2015 Share Price and Financial Analysis
  • Exhibit 14.36: Mesoblast Revenue Generated FY2014-FY2015
  • Exhibit 14.37: Mesoblast R&D Expenditure FY2014-FY2015
  • Exhibit 14.38: NuVasive Biologics Portfolio
  • Exhibit 14.39: NuVasive Global Revenue 2013-2015
  • Exhibit 14.40: NuVasive NON GAAP Operating Profit Margin 2013-2015
  • Exhibit 14.41: NuVasive Spinal Surgery Product and Biologic Revenue Breakdown 2013-2015
  • Exhibit 14.42: NuVasive USA and International Revenue Breakdown 2015
  • Exhibit 14.43: NuVasive Corporate Strategy Going Forward
  • Exhibit 14.44: Osiris Therapeutics Current Product Portfolio
  • Exhibit 14.45: Osiris Therapeutics Product Pipeline by Indication, Preclinical, Clinical and Market Stage
  • Exhibit 14.46: Exhibit Plasticel Partnerships and Collaborations with Industry and Academic Institutions
  • Exhibit 14.47: Pluristem Therapeutics Company Pipeline Portfolio by Product, Indication, Location & Phase
  • Exhibit 14.48: Pluristem Therapeutics Production of PLX-PAD & PLX-R18
  • Exhibit 14.49: Pluristem Therapeutics Revenue 2013-2015
  • Exhibit 14.50: Pluristem Therapeutics R&D Costs 2013-2015
  • Exhibit 14.51: Pfizer Stem Cell Policy
  • Exhibit 14.52: StemCell Inc Manufacturing Steps of Hu-CNS-SC Product
  • Exhibit 14.53: STEMCELL Technologies Product Portfolio
  • Exhibit 14.54: STEMCELL Technologies Brand Portfolio
  • Exhibit 14.55: Takara Bio Sales Revenue 2014-2019
  • Exhibit 14.56: Takara Bio Operating Sales 2014-2019
  • Exhibit 14.57: Takara BioIndustry Sales Revenue 2014-2018
  • Exhibit 14.58: Takara Bio Sales by Geographic Region FY2016
  • Exhibit 14.59: Tigenix Key Intellectual Property Patent Portfolio
  • Exhibit 14.60: Comprehensive List of Companies in the Stem Cell & Regenerative Medicine Industry
  • Exhibit 15.1: Advantages, Weaknesses, Opporunities & Threats of Allogenic & Autologous Stem Cells
  • Exhibit 15.2: Opportunistic Therapeutic Indications as Decided by Senior Key Opinion Leaders
Back to Top